Precision medicine market seen topping $137B by 2030

The Business Research Company says the global precision medicine market is headed for more than $137 billion by 2030, powered by gene sequencing, AI and demand for tailored therapies. North America is expected to lead the market, while Roche held the largest share in 2025.

Why it matters: - Precision medicine is moving deeper into mainstream care as health systems shift toward treatments based on genetics, biomarkers and disease subtype. - The market’s growth signals rising demand for more targeted diagnostics, oncology tools and data-driven therapy selection. - The forecast also points to bigger commercial opportunities across sequencing, bioinformatics, drug discovery and companion diagnostics.

What happened: - The Business Research Company published its Precision Medicine Global Market Report 2026 on Oct. 27, 2026. - The report says the precision medicine market is on track to exceed $137 billion by 2030. - The broader personalized medicine market, which includes precision medicine, is forecast to reach about $822 billion by 2030. - Precision medicine is projected to represent about 5% of the $2,496 billion pharmaceuticals industry by 2030. - The report includes market sizing, trends, forecasts and regional analysis through 2035. - The full report is available online.

The details: - North America is forecast to remain the largest regional market in 2030 at $53 billion, up from $31 billion in 2025. - North America’s market is projected to grow at a 11% CAGR. - The United States is expected to be the largest single-country market in 2030 at $49 billion, up from $29 billion in 2025. - The U.S. market is also projected to grow at a 11% CAGR. - Gene sequencing is expected to lead technology categories with a 30% share and $41 billion in market value by 2030. - Precision medicine applications span oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and other conditions. - End users include pharmaceutical companies, diagnostics firms, healthcare organizations and IT providers. - The report says genomic sequencing adoption adds about 2.2% annual growth to the market. - Rising chronic and genetic disease prevalence adds about 1.9% yearly growth. - AI integration contributes roughly 1.2% annual growth. - Technology segments such as big data analytics, bioinformatics, gene sequencing, drug discovery and companion diagnostics are expected to add more than $48 billion by 2030. - Segment growth from 2025 to 2030 is projected at $6 billion for big data analytics, $10 billion for bioinformatics, $14 billion for gene sequencing, $13 billion for drug discovery and $5 billion for companion diagnostics. - Roche Holding AG led the global precision medicine market in 2025 with 6% of sales. - The top 10 companies accounted for 18% of total revenue in 2025. - The report lists Roche, Illumina, QIAGEN, Abbott, Novartis, AstraZeneca, Pfizer, Agilent, Merck, Amgen and other companies as key players. - The report also names major raw material and technology suppliers, distributors and end users across the precision medicine ecosystem. - In August 2024, Illumina received FDA approval for its TruSight Oncology Comprehensive test, which includes companion diagnostic indications for multiple therapies and analyzes more than 500 genes from a single tumor sample. - The company says the report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics. - A sample request is available at Request a free sample.

Between the lines: - The market remains fragmented despite strong growth, which suggests no single player has overwhelming control over precision medicine. - High regulatory barriers, complex clinical validation and the need for reliable genomic testing continue to shape competition. - The report’s emphasis on AI, multi-omics and real-world evidence shows where vendors are competing for differentiation. - The focus on oncology and companion diagnostics reflects where precision medicine is already producing the clearest commercial and clinical gains.

What’s next: - Continued adoption of next-generation sequencing, molecular diagnostics and digital health platforms should keep the market expanding through 2030. - Pharma, diagnostics and healthcare partnerships are likely to remain central to product development and commercialization. - More clinical use of AI and cloud-based genomic platforms is expected to support faster patient stratification and therapy selection. - Competitive pressure is likely to stay high as companies race to build stronger biomarker, sequencing and companion diagnostic capabilities.

The bottom line: - Precision medicine is becoming a larger, more data-intensive part of healthcare, with sequencing and AI driving the next phase of growth.